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Abstract
Purpose: GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase
A2 (Lp-PLA2), which was in development as a potential treatment for Alzheimer’s disease (AD).
In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form
of the inhibitor, [18F]GSK2647544, was manufactured for use in a positron emission tomography
(PET) biodistribution study.
Procedures: [18F]GSK2647544 was produced using a novel, copper iodide (Cu(I)) mediated,
[18F]trifluoromethylation methodology. Healthy male subjects (n = 4, age range 34–42) received
an oral dose of unlabelled GSK2647544 (100 mg) and after 2 h an intravenous (iv) injection of
[18F]GSK2647544 (average injected activity and mass were 106 ± 47 MBq and 179 ± 55 μg,
respectively) followed by dynamic PET scans for 120 min. Defined regions of interest (ROI)
throughout the brain were used to obtain regional time-activity curves (TACs) and compartmen-
tal modelling analysis used to estimate the primary outcome measure, whole brain volume of
distribution (VT). Secondary PK and safety endpoints were also recorded.
Results: PET dynamic data were successfully obtained from all four subjects and there were no
clinically significant variations of the safety endpoints. Inspection of the TACs indicated a relatively
homogenous uptake of [18F]GSK2647544 across all the ROIs examined. The mean whole brain VT
was 0.56 (95%CI, 0.41–0.72). SecondaryPKparameters, Cmax (geometricmean) and Tmax (median),
were 354 ng/ml and 1.4 h, respectively. Metabolism of GSK2647544 was relatively consistent across
subjects, with 20–40 % of the parent compound [18F]GSK2647544 present after 120 min.
Electronic supplementary material The online version of this article
(doi:10.1007/s11307-016-0982-5) contains supplementary material, which
is available to authorized users.
Correspondence to: Andrew Lockhart; e-mail: andrew.2.lockhart@gsk.com
Conclusions: The study provides evidence that GSK2647544 is able to cross the blood brain
barrier in healthy male subjects leading to a measurable brain exposure. The administered
doses of GSK2647544 were well tolerated. Exploratory modelling suggested that a twice-daily
dose of 102 mg, at steady state, would provide ~80 % trough inhibition of brain Lp-PLA2 activity.
Trial Registration: Clintrials.gov: NCT01924858.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder that accounts for ~60–70 % of 947.5 million
people affected worldwide by dementia [1]. The disease is
characterised neuropathologically by the formation of
amyloid-beta containing senile plaques and tau containing
neurofibrillary tangles and clinically by cognitive deficits
that over time result in profound cognitive and functional
impairment [2]. AD remains an area of high unmet medical
need as currently available treatment options for AD are
limited and provide only modest, short-term symptomatic
benefit [3].
Lipoprotein-associated phospholipase A2 (Lp-PLA2),
also known as plasma platelet activating factor
acetylhydrolase (PAF-AH), is a member of the phospholi-
pase A2 superfamily of enzymes [4]. Lp-PLA2 is primarily
secreted by monocyte-derived macrophages and its expres-
sion is upregulated during inflammation [5]. Lp-PLA2
circulates in plasma as a complex with low-density lipopro-
tein (LDL) and, to a lesser extent, with high-density
lipoprotein (HDL) and lipoprotein(a) [5, 6]. Lp-PLA2 has
been studied extensively as a marker of cardiovascular risk,
and inhibitors of the enzyme were initially developed to
counter the role of products derived from oxidised low-
density lipoproteins in driving the vascular inflammation [6].
Preclinical evidence suggested beneficial effects of Lp-
PLA2 inhibition on blood brain permeability and brain
amyloid-beta peptide 1-42 (Aβ1-42) deposition [7]. Prelim-
inary clinical evidence that targeting this pathway may
provide a novel treatment to slow the progression of AD
comes from a Phase 2a study with the Lp-PLA2 inhibitor,
rilapladib (SB659032) [8]. Lp-PLA2 is also present in the
human central nervous system (CNS) [9], and its specific
activity can be detected in cerebrospinal fluid [8, 10].
Pharmacological inhibition of this central pool of Lp-PLA2,
in addition to the plasma pool, has the potential to provide
an additional interventional mechanism for the treatment of
AD and other neurological indications.
GSK2647544 is a novel potent and specific inhibitor of
Lp-PLA2, and data indicated that the molecule was able to
cross the BBB of preclinical species [GSK data on file]. At
the time of initiating the PET study, GSK2647544 had
successfully completed a first time in human (FTIH) clinical
trial (Clinicaltrials.gov: NCT01702467) [11]. In order to
enable the PET biodistribution study, options for
radiolabelling of GSK2647544 had to be identified. The
chemical structure of the drug presented a significant
challenge to conventional radiolabelling approaches due to
the lack of functional groups amenable to existing PET
chemistry approaches. Recently published work suggested
the potential to insert the PET isotope [18F]fluoride in the
trifluoromethyl position on the molecule [12] and a three-
step synthesis was developed (Fig. 1), which was success-
fully implemented, optimised and transferred to a fully
automated setup. Subsequently, the process was fully
validated for clinical use.
The primary objective of the study was to investigate the
brain penetration of GSK2647544 through determination of
the whole brain PET volume of distribution (VT) [13] of
[18F]GSK2647544, following administration of an oral dose
of the unlabelled drug (100 mg) 2 h prior to the PET scan.
Secondary endpoints included safety measures and PK
parameters. An exploratory analysis was also performed to
estimate the dosing regimen required to achieve, at trough, a
level of ~80 % brain Lp-PLA2 inhibition. After 4 subjects
had successfully completed the study, a protocol amendment
was undertaken to permit an evaluation of the brain
penetration of [18F]GSK2647544 in the absence of the oral
dose of GSK2647544. The amended protocol was not
initiated as the PET study was terminated due to a finding
f rom a separa te c l in ica l pharmaco logy s tudy
(Clinicaltrials.gov: NCT01978327), running in parallel,
which indicated that GSK2657544 had a potentially clini-
cally significant drug–drug interaction (DDI) [14].
Material and Methods
Radiopharmaceutical Preparation
[18F]GSK2647544was prepared in a three-step, two-pots synthesis, with
intermediate preparation of 4-chloro-3-([18F]trifluoromethyl)phenol
(Fig. 1). In brief, cyclotron-derived [18F]fluoride was first reacted with
methyl chlorodifluoroacetate (40 μl) and 4-chloro-3-iodophenyl acetate
precursor (9–10 mg) in anhydrous DMF (400 μl) at 150 °C for 15 min.
The resulting ester was hydrolysed with tetrabutylammonium hydroxide
(1 M in methanol) at 140 °C for 12 min. The formed 4-chloro-3-
([18F]trifluoromethyl)phenol was transferred to a potassium iodide
solution containing 5 g of potassium iodide, 18 ml of water and 2 ml
of acetonitrile in order to allow intermediate purification by solid-phase
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extraction using a C18 SepPak. The SepPak column was washed with
10 ml of a water/acetonitrile solution (90/10, v/v) upon which excess
water was removed using a stream of argon for 2 min. 4-Chloro-3-
([18F]trifluoromethyl)phenol was released from the SepPak using 4.5 ml
of anhydrous diethyl ether. Any trace of water remaining was removed
by passing the ether through an online sodium sulphate cartridge and a
4 Å molecular sieve cartridge into a second reactor. The diethyl ether
was evaporated at 70 °C under a stream of helium, before being reacted
with a bromide-containing precursor (2-(4-bromophenethoxy)-5-
(pyrimidin-5-ylmethyl)pyrimidin-4(1H)-one) in anhydrous diglyme
(500 μl) at 170 °C for 25 min in the presence of caesium carbonate
(48–52 mg) and copper iodide (7–8 mg) to form [18F]GSK2647544.
Purification of [18F]GSK2647544 was achieved after dilution with
3.5 ml of mobile phase prior to injection onto a reverse-phase high-
performance liquid chromatography system (HPLC; Column: Agilent
ZORBAX SB C18, 250 × 9.4 mm, 5 μm, Mobile phase: ammonium
formate 50 mM pH 4/acetonitrile [50/50, v/v], flow: 8 ml/min,
wavelength: 254 nm). The fraction containing the product was collected
and HPLC solvent was removed by means of SepPak reformulation
approach to give a product for intravenous (iv) administration in 11 mL
of 0.9 % saline containing ethanol (to a maximum of 14 % v/v) and
hydroxypropyl-β-cyclodextrin (to a maximum of 20 % w/w). The
resulting formulated solution was filtered through a 0.2 μm sterile filter
(Millipore Millex GV, 0.22 μm, 33 mm) into its final sterile container.
Qual i ty cont ro l methods for c l in ica l ba tches of
[18F]GSK2647544 were developed in accordance with the Euro-
pean Pharmacopoeia guidelines [15]: residual organic solvents (Ph.
Eur. 5.4), pH (Ph. Eur. 2.2.3), pyrogen test (Limulus Amebocyte
Lysate (LAL) chromogenic kinetic method, Ph. Eur. 2.6.14), filter
integrity test (bubble-point measurement, Ph. Eur. 5.1.1) and
sterility test (Ph. Eur. 2.6.1). Other tests included visual appearance,
radionuclidic identity and purity.
Radiochemical purity, specific activity and identity were
determined by analytical HPLC (Column: Agilent SB-Phenyl
[3.5 μm, 4.6 × 100 mm], mobile phase: water [0.2%TFA]/methanol
{30/70, v/v}, flow: 1 ml/min, wavelength: 235 nm, T = 50 °C).
Study Design
This was an open label, non-randomised study to investigate the brain
penetration of [18F]GSK2647544 by PET and the study protocol allowed
for up to 8 evaluable subjects to be scanned. The sample size was based
on prior experience from similar brain biodistribution studies. All PET
and magnetic resonance imaging (MRI) scans were conducted at
Imanova Limited (Burlington Danes Building, Imperial College London,
Hammersmith Hospital, Du Cane Road, London W12 0NN, UK) and
healthy male subjects were recruited by Hammersmith Medicines
Research (HMR, Cumberland Avenue, London, NW10 7EW, UK).
Subjects
This study was conducted in accordance with the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) Good
Clinical Practice (GCP) and all applicable subject privacy require-
ments, and, the ethical principles that are outlined in the
Declaration of Helsinki 2008. The original and amended protocols
were reviewed and approved by National Research Ethics Service
of the UK National Health Service. The study was monitored in
accordance with ICH E6, Section 5.18. Written informed consent
was obtained from each subject in the study prior to the
performance of any study-specific procedures.
Healthy male subjects between 30 and 55 years were recruited
for the study, with a body weight of ≥50 kg and body mass index
(BMI) within the range 19.0 to 29.0 kg/m2 (inclusive). Eligibility
was also based on no abnormalities in past medical history,
physical examination, vital signs, clinical laboratory parameters
and electrocardiography (ECG). See Supplementary Materials for
full details of eligibility criteria.
After confirmation that a subject met all eligibility criteria, a
structural MRI scan was performed at Imanova Limited to provide a
T1-weighted image for co-registration with their PET data. High-
resolution (HR) 3D volumetric MRI scans (MPRAGE sequence: TI =
900 ms, TR = 3000 ms, TE = 3.66 ms, flip angle = 9°, voxel size =
1 mm3, 160 slices) were acquired for this purpose on a 3 T Tim Trio
MRI scanner system (Siemens Healthcare, Erlangen Germany).
Imaging Procedure
On the day of the PET study, subjects were prepared for the PET
scans and received an oral dose of GSK2647544 (100 mg) 2 h
Fig. 1 Multi-step approach to the preparation of [18F]GSK2647544 using the methodology described in [12]. A bromide-
containing precursor, 2-(4-bromophenethoxy)-5-(pyrimidin-5-ylmethyl)pyrimidin-4(1H)-one,was coupled to the 4-chloro-3-
([18F]trifluoromethyl)phenol reaction product to generate [18F]GSK2647544.
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before administration of [18F]GSK2647544 and the start of the PET
scan. Based on the FTIH data [11], this would result in acute blood
exposures that were estimated to be within the range required for
future therapeutic studies and would help ensure that the measured
brain penetration of [18F]GSK2647544 was more reflective of this
setting.
Subjects were positioned in the PET scanner, after the insertion
of a radial artery cannula under local anaesthesia and a venous
cannula in an antecubital or forearm vein. The subject’s head was
positioned comfortably with soft restraints used to reduce head
motion during data acquisition. Dynamic PET data were acquired
on one of two Siemens Biograph 6 PET/CT scanners at Imanova
(Siemens Healthcare, Erlangen, Germany). A low‐dose CT scan
was performed on each subject immediately before each PET scan
in order to estimate attenuation. Following iv bolus injection of the
radiotracer, dynamic emission data were acquired for 120 min
(frame durations: 8 × 15 s, 3 × 60 s, 5 × 120 s, 5 × 300 s, 5 × 600 s).
The dynamic images were reconstructed using Fourier rebinning
and a 2D filtered discrete inverse Fourier transform algorithm with
5 mm isotropic Gaussian filter on a 128 × 128 matrix with 2.6 zoom
giving 2 mm isotropic voxels. Corrections were applied for
attenuation, randoms and scatter.
Sampling of radial arterial blood for radioactivity and radioac-
tive metabolites was performed throughout the PET scan, with
continuous 5 ml/min for 15 min and discrete sampling from 5 to
120 min post-injection. Whole-blood and plasma radioactivity
levels were measured using a Wallac 1470 Wizard gamma counter
(Perkin Elmer, Seer Green, UK).
Metabolite Analysis
Arterial plasma samples for radioactive metabolite analysis were
collected at 5, 10, 20, 30, 50, 70, 90 and 120 min post
administration of [18F]GSK2647544 and were further processed
by HPLC using the so-called ‘Hilton’ method [16] to determine the
fraction of radioactivity corresponding to the intact parent. Plasma
samples (0.5–1 ml) were treated with urea (8 M) to eliminate
plasma protein binding, diluted with an equivalent volume of water
and filtered through a PTFE membrane. The HPLC consisted of an
Agilent 1200 series system (Agilent, Santa Clara, US), including an
isocratic pump, a binary pump, a UV detector, a fraction collector
and four automated 6-port valves. The capture column was a
Biotrap 500MS Column (20 × 4.0 mm, 5 μm) and the analytical
column was an Agilent Zorbax Eclipse XDB-C18 (150 × 4.6 mm,
5 μm). The isocratic pump was run at a flow of 2 ml/min using a
5 % acetonitrile in water solution. The binary pump eluent was a
mixture of 25 mM pH 3 ammonium formate buffer and acetonitrile.
The binary pump was run at a flow of 2 ml/min with following
gradient: 5 % acetonitrile from 0 to 4 min, 5 to 95 % acetonitrile
from 4 to 7 min, 95 % acetonitrile from 7 to 10 min. UV signal was
recorded at 330 nm and fractions were collected every 20 s for
gamma counting.
Free Fraction Measurement
The non-protein bound fraction of [18F]GSK2647544 in arterial
plasma (fp) was quantified using the following methodology.
An aliquot of [18F]GSK2647544 was added to approximately
1 ml of plasma collected from the subject prior to tracer
administration or to 1 ml Tris buffer (pH = 7.4, Sigma).
Triplicate 50 μl aliquots of spiked plasma and Tris buffer
were prepared for gamma counting using an automated gamma
counter (Perkin Elmer, Massachusetts, US). Subsequently,
triplicate 200 μl aliquots of spiked plasma and Tris buffer
were pipetted into ultrafiltration units (Amicon Ultra-0.5 ml
centrifugal filters, Merck Millipore) pre-treated with a 5 %
TWEEN 80 solution. Filters were centrifuged at room temper-
ature for 15 min at 10,000 rpm. At the end of centrifugation,
50 μl plasma and Tris ultrafiltrate were counted using the
automated gamma counter and fp was calculated as the ratio of
ultrafiltrate to total activity concentrations corrected for non-
specific fi l ter binding. There was no evidence of
[18F]GSK2647544 being metabolised during this procedure.
Imaging Data Analysis
Dynamic PET emission and associated structural MRI images were
analysed using MIAKATTM, a software developed by Imanova
Limited [17]. Dynamic PET emission data was corrected for motion
and registered to the structural T1 MRI image. The Imanova
Limited neuroanatomical atlas was non‐linearly deformed into the
individual’s space in order to generate a personalised anatomical
parcellation of the brain. Whole brain (primary endpoint), global
grey matter, global white matter, cortex, thalamus and subcortical
grey matter were analysed as regions of interest (ROIs) The warped
ROIs were applied to the dynamic emission data to generate
regional time-activity curves (TACs). Compartmental model anal-
ysis was investigated to derive partition coefficient (VT) for
GSK2647544 for the whole brain as well as for the ROIs. A fixed
blood volume correction (5 %) was included in the One Tissue
Compartment Model that was selected to derive VT.
The single passage extraction fraction (E) for [18F]GSK2647544
was calculated as follows: E = K1/F, where K1 is average rate
constant for transfer of GSK2647544 from arterial plasma to tissue
and F is the brain perfusion, with a value of 0.6 ml/min/cm3 [18].
Bioanalysis of GSK2647544 Following Oral
Dosing
Blood samples for the analysis of GSK2647544 plasma concentra-
tion were collected at 15, 30, 60, 120 and 240 min post oral dosing
into EDTA-K3 tubes, mixed by inversion and immediately cooled
to 2–4 °C. Within 50 min of collection, the samples were
centrifuged at 1500 g for 10 min at ~4 °C in a swing bucket
centrifuge. Plasma was harvested into uniquely labelled polypro-
pylene screw-cap storage tubes, frozen at −20 °C and shipped on
dry ice to GlaxosmithKline (Ware, UK) to determine the plasma
concentrations of GSK2647544 using a validated analytical method
based on protein precipitation, followed by HPLC/MS/MS analysis
[GSK method on file].
Plasma concentration-time data was analysed using WinNonlin
Professional Edition (Pharsight Corporation, Mountain View, CA).
Calculations were based on the actual sampling times recorded
during the study. From the plasma concentration-time data, the
maximum observed plasma concentration (Cmax) and time to Cmax
(Tmax) were determined.
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Exploratory Analysis for Estimating Brain Lp-
PLA2 Enzyme Activity Inhibition
Available clinical data indicated that there is a direct Emax-type
relationship between plasma Lp-PLA2 enzyme activity inhibition
and GSK2647544 plasma concentration [11, 14]. Therefore, such a
relationship was assumed between brain Lp-PLA2 enzyme activity
inhibition and GSK2647544 brain concentration. The percentage
brain Lp-PLA2 activity inhibition was calculated using the
following equation:
% LpPLA2 inhibition ¼ Cbrain; fu
Cbrain; fu þ IC50brain; fu  100%
In which, Cbrain,fu was the free drug concentration of
GSK2647544 in the brain, IC50brain,fu was the free drug potency
of GSK2647544 in the brain. The IC50brain,fu (0.008 nM) for
GSK2647544 was determined using post-mortem human brain
tissue [GSK data on file]. The Cbrain,fu was calculated as: Cplasma ×
B : P × VT × fubrain, in which, Cplasma was the plasma concentration,
B:P was the blood-to-plasma distribution ratio of GSK2647544
(0.606) [GSK data on file], fubrain was the free fraction of
GSK2647544 in the brain (0.07 %) [GSK data on file]. For a
given bid dose of GSK2647544, Cplasma at trough could be
predicted based on the PK model derived from the previous clinical
studies [11, 14].
Results
Brain Biodistribution of GSK2647544
[18F]GSK2647544 was successfully prepared using the
method described in sufficient yield to support the clinical
study objectives (624 ± 192 MBq, 1.0 ± 0.3 % radiochem-
ical yield, 0.5 ± 0.1 GBq/μmol, n = 8). The radiochemical
purity of [18F]GSK2647544, based on analytical radio-
HPLC, was recorded to be 100 % for all batches used (n =
8) as no other radioactive peaks could be observed.
[18F]GSK2647544 co-eluted with authentic reference as
measured by analytical HPLC, confirming identity. Rela-
tively high mass was observed for the final product
suggesting inherent isotopic dilution as a result of the
chemical process. These results are in agreement with
previous findings [12].
Four male subjects who had an average age of 37 years
(age range 34–42) were evaluated in the study. Two hours
after oral dosing with unlabelled GSK2647544 (100 mg), the
radiolabelled drug was delivered as a slow bolus iv infusion,
with an average injected activity of 106 ± 47 MBq and an
average injected mass of 179 ± 55 μg. PET dynamic data
were successfully acquired from all four subjects.
Visual inspection of the PET data indicated a consistent
entry of [18F]GSK2647544 in the brain and a relatively
homogenous distribution of radioactivity across the brain
(Fig. 2). The lack of significant regional heterogeneity was
confirmed by the inspection of the regional TACs for
[18F]GSK2647544, although the regional SUVs of subject
4 were generally lower than those of the other subjects
(Fig. 3). Analysis of arterial blood and plasma samples
allowed the generation of a metabolite corrected arterial
plasma input function to enable kinetic analysis of the
dynamic image data. Metabolism of GSK2647544 was
relatively consistent across the subjects, with 20–40 % of
the parent compound present after 120 min (Fig. 4;
Supplementary Figure). The presence of a more lipophilic
radiometabolite eluting prior to the parent was consistent
across scans and was not seen during preclinical method
development. While it cannot be formally excluded that the
radiometabolite may cross the BBB, good fits were achieved
for the kinetic analysis using the metabolite corrected arterial
input function, indicating that any contribution of lipophilic
metabolites was likely to be marginal.
Fig. 2 Images showing the summed radioactivity (60–90 min) in the brain of [18F]GSK2647544 (left four panels) with T1
weighted structural MRI scan show for subject 4 (right panel). All four subjects received a 100 mg of unlabelled GSK2647544
followed 2 h later by a bolus injection of [18F]GSK2647544 (injected dose: 106 ± 47 MBq). The uptake is expressed
standardised uptake values (SUV).
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A one tissue compartmental model (1TCM) provided
the most parsimonious description of the data based on
the use of a quantitative metric, Akaike information
criterion [19]. Application of the 1TCM produced
consistent estimates of the model parameters with values
reported for VT and K1 (Table 1). The primary outcome
measure, whole brain VT for [
18F]GSK2647544, was
estimated to be 0.56 (95 % CI, 0.41–0.72). The low
variability (G20 %) of the VT values across all regions
was consistent with the visual inspection of the images
and the regional TACs and supported the view that
[18F]GSK2647544, when dosed with 100 mg of
unlabelled drug, was homogenously distributed through-
out the brain. Using an average K1 value for the whole
brain of 0.0101 ml/gm/min (Table 1), the single passage
extraction fraction (E) for [18F]GSK2647544 was esti-
mated to be ~2 %.
PK analysis of the oral dose of unlabelled GSK2647544
provided estimates of Cmax (354.0 ng/ml, coefficient
variation of 19.1 %) and Tmax (median 1.4 h, range 1.02 to
6.38 h).
Exploratory modelling suggested that a twice-daily dose
of 102 mg, at steady state, would provide ~80 % trough
inhibition of brain Lp-PLA2 activity.
Subject Safety
The doses of GSK2647544 administered in this study were
well tolerated. All four subjects enrolled in the study
completed the protocol and there were no serious adverse
events (SAEs), no variation of vital signs and ECG
measurements and no clinically significant out of range
safety lab results. All the adverse events (AEs) reported
during this study were transient and of mild to moderate
intensity (Table 2).
Discussion
The ability to inhibit brain Lp-PLA2, in addition to blood
Lp-PLA2, is a potentially important feature of GSK2647544.
In v ivo imaging using PET and radiolabel led
[18F]GSK2647544 was used to explore brain exposure in
humans through measurement of the whole brain PET
volume of distribution, VT, which was the primary outcome
measure for the study. The measured VT for
[18F]GSK2647544 was 0.56 (95 % CI, 0.41–0.72) in the
presence of the unlabelled GSK2647544 (100 mg), indicat-
ing that the drug is able to enter the brain. Visual inspection
of the scan data (Fig. 1) and comparison of the regional
Fig. 3 Regional [18F]GSK2647544 time-activity curves for each of the subjects. GM grey matter, WM white matter.
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TACs (Fig. 2) indicated that the distribution of the
radiolabelled drug was broadly homogenous (Table 1). The
generally lower regional SUVs for subject 4 were not readily
explained by the comparison of the respective PK parame-
ters from each subject (Supplementary Table) suggesting
that other factors are likely involved. The secondary PK
endpoints (Cmax and Tmax) were of broadly similar magni-
tude to that found in the other clinical studies of
GSK2647544 [11, 14]. The doses of GSK2647544 admin-
istered in this study were well tolerated.
The data from the current study broadly supported the
preclinical investigations of the brain penetration of
GSK2647544, where blood-to-brain (Kp) ratios of between
0.4 and 0.75 were observed in mice and rats [GSK data on
file] (Table 3). Comparison of additional in vitro data
suggests that GSK2647544 is highly protein bound across
species, reflected in the low plasma free fraction (fP) values,
and that the brain free fraction (fND) generally appeared
slightly higher. Given the additional observations that
GSK2647544 was not a Pgp substrate and that its passive
permeability across a cellular monolayer model was not
limiting [GSK data on file], the data from the biodistribution
study was broadly consistent with the preclinical findings.
As part of a dosimetry study performed in Sprague-Dawley
rats with [18F]GSK2647544, a substudy was undertaken to
examine the brain penetration of the drug, which found the
blood corrected SUV to be ~0.3 [GSK data on file]. No
further investigations were performed on the apparently
lower overall brain penetration of GSK2647544 observed in
this study, and the data did not change the overall design of
the clinical PET study. A degree of caution needs to be
applied in the cross-comparison and interpretation of the
preclinical and clinical data as a number of methodological
differences exist across the studies (e.g., route of adminis-
tration, doses received, observational periods and modelling/
data analysis methods).
The preparation of a suitable PET labelled homologue of
GSK2647544 provided a significant challenge given the
limited availability of functional groups amenable to introduc-
tion of the two principal PET isotopes carbon-11 (T1/2 =
20.4 min) or fluorine-18 (T1/2 = 109.8 min). A novel chemical
pathway [12] provided a potential means to introduce F-18 into
the trifluoromethyl moiety of GSK2647544. A multi-step
approach, starting from a small initial building block to allow
introduction of fluorine-18, had to be designed, as direct
labelling of the trifluoromethyl group did not work. It should
be noted as well that due to very high retention of the
radiotracer on the sterilising filter, hydroxypropyl-β–cyclodex-
trin was successfully used as an additive in the formulation of
the sterile [18F]GSK2647544 concentrate solution for injec-
tion. To our knowledge, this additive has not been applied in
PET formulations to date, which may in part be due to limited
availability of a pharmaceutical grade product.
The current study provides a demonstration of the utility
of this new radiochemical approach and provides easy
access to F-18 radiolabelled trifluoromethyl groups, fre-
quently used to enhance pharmacokinetic properties. This
reaction involves only commercially available reagents and
Fig. 4 Time course of the parent [18F]GSK2647544 fraction
in arterial plasma over the duration of the PET scan.
Table 1. Summary of VT and K1 values for all 4 subjects across whole brain and ROIs defined in the study
Volume of distribution VT Rate constant K1 (mL/gm/min)
Brain region Mean (95 % CI) Standard deviation Mean (95 % CI) Standard deviation
Whole brain 0.56 (0.41,0.72) 0.098 0.0101 (0.0086,0.0117) 0.00097
Cortex 0.52 (0.37,0.66) 0.092 0.0087 (0.0071,0.0103) 0.00100
Global grey matter 0.52 (0.40,0.63) 0.073 0.0099 (0.0093,0.0105) 0.00039
Global white matter 0.50 (0.39,0.61) 0.067 0.0094 (0.0084,0.0105) 0.00066
Subcortical grey matter 0.53 (0.42,0.65) 0.070 0.0117 (0.0104,0.0130) 0.00082
Thalamus 0.54 (0.38,0.71) 0.104 0.0096 (0.0077,0.0114) 0.00116
VT volume of distribution for the total radioligand in tissue, K1 rate constant for transfer from arterial plasma to tissue
Table 2. Summary of all adverse events for all four subjects
Total adverse events (n) N = 4 subjects
n (%)
Any AE 3 (75)
Any AE related to investigational product 0
Headache 1 (25)
Paraesthesia 1 (25)
Upper respiratory tract infection 1 (25)
Acne 1 (25)
M. Huiban et al.: Human Brain Biodistribution of [18F]GSK2647544 159
readily accessible iodinated precursors. The generation in
situ of the [18F]CF3Cu reagent involves the formation of a
carbene intermediate, which explains the observed low
specific activity values. As a result, this technology could
not be applied where low mass is required, e.g., brain
neuroreceptor occupancy studies, but, given the high
prevalence of the trifluoromethyl group, it is highly relevant
for labelling candidate drug molecules to understand their
CNS biodistribution and in combination with described
approach for GSK2647544 provides a means to estimate
target occupancy in the absence of a specific tool compound.
An additional potential limitation of this technique is the low
radiochemical yield which may make it unsuitable in
situations where high volumes of scans need to be
performed (e.g., as a diagnostic tool) but in the current
situation the yield was fit-for-purpose. Nevertheless, rela-
tively straightforward PET biodistribution studies, using this
labelling methodology, have the potential to be utilised early
in clinical development and can add valuable information for
early compound progression decisions.
Due to the decision to terminate the PET study, due to the
separate DDI finding [14], an amended protocol that would
have permitted the administration of [18F]GSK2647544 in
the absence of the 100 mg dose of unlabelled drug was not
initiated. As the observed yield of [18F]GSK2647544 was
~5- to 10-fold higher than anticipated during the clinical
manufacture, this provided the opportunity to determine the
whole brain VT of [
18F]GSK2647544 under more tracer-like
conditions (i.e., in the absence of the loading dose of
unlabelled drug). This approach would have facilitated
comparison with the currently determined whole brain VT
values to explore whether the mode of entry of the drug was
potentially through passive diffusion or subject to transporter
effects, thereby providing valuable reverse-translational
validation of the preclinical models used to measure brain
penetration. Therefore, this aspect was considered further
through the following exploratory analysis.
Molecules entering the brain by passive diffusion are
expected to reach similar free concentrations at equilibrium.
With this in mind, it can be shown that the ratio of the in vitro
derived plasma (fP) and brain (fND) free fractions will be equal
to the equilibrium partition coefficient for the drug at
equilibrium [20]. As the PET VT, for regions with minimal
displaceable binding, can be shown to be equivalent to the
equilibrium partition coefficient, brain entry by passive
diffusion can be assumed if VT≅ fP/fND [20]. The data from
this study provide little evidence for a displaceable binding
component with [18F]GSK2647544 due to the lack of regional
heterogeneity and the high dose of GSK2647544 (100mg) pre‐
administered before the scan. For GSK2647544, based on an
equilibrium dialysis method using post-mortem human brain
homogenates, fP and fND were estimated to be 0.0004 and
0.00068 [GSK data on file] (Table 3), respectively. A
comparison of the mean value of VT (0.56, Table 2) with fP/
fND (0.59, i.e., 0.0004/0.00068) suggested that due to their
numerical similarity, the entry of GSK2647544 was consistent
with a passive diffusion mechanism and therefore, it may be
expected that at equilibrium, the free brain concentration of
GSK2647544 will be equivalent to the free plasma concentra-
tion (i.e., fND≅ fP).
There are limited reports relating to the molecular
imaging of lipid-related metabolism in the brain, one such
example is the C-11 labelled form of arachidonic acid (AA)
that has been used in man to investigate dopaminergic
neurotransmission [21] and neuroinflammation [22]. AA is a
polyunsaturated fatty acid that is found incorporated high
concentrations in brain phospholipids and the metabolism of
AA and its oxidatively modified form, F2-isoprostane, has
been linked with cPLA2 and Lp-PLA2, respectively [23, 24].
Although Lp-PLA2 has been implicated in F2-isoprostane
metabolism, the evidence is mixed and may indicate a more
significant role for other phospholipases [24, 25]. The
further evaluation of potential Lp-PLA2 tracers and devel-
opment of further molecular imaging agents to probe brain
lipid metabolism [26] can only serve to improve our
understanding of disease-related changes in these important
pathways.
Conclusion
In conclusion, a novel synthetic method was used to
generate [18F]GSK2647544 and this was successfully ap-
plied in the current PET biodistribution study. The findings
from this study indicate that GSK2647544 is able to cross
the blood brain barrier and enter the human brain. An
exploratory analysis of the data indicated that a dose of
102 mg, twice daily at steady state would be sufficient to
reach, at trough, ~80 % brain Lp-PLA2 inhibition.
Table 3. Listing of available parameters for preclinical species and humans. Free fraction data was generated using equilibrium dialysis methods and for fND
used brain homogenates. Human tissues were sourced from the Brain and Body Donation Program at Banner Sun Health Research Institute (Arizona, US) and
had ethical approval for research use as part of the material transfer agreement
Free fraction, plasma (fp) mean ± SD Free fraction, brain (fND) mean ± SD Kp/VT
1
Mouse Not determined 0.00068 ± 0.00002, n = 3 0.41a
Rat 0.0005 ± 0.0001, n = 3 0.00071 ± 0.00002, n = 3 0.75b, 0.64c
Human 0.0004 ± 0.00003, n = 3 0.00068 ± 0.00015, n = 6 0.561
a2 mg/kg, intraperitonal, AUC0–4h
b2 mg/kg, oral, AUC0–7h
c10 mg/kg, oral, AUC0–7h
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